✨ Free AI Report
Insmed Incorporated: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Insmed Incorporated
Company Research

Insmed Incorporated: Business Overview, Financials & Competitive Analysis

Insmed develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company is at a critical inflection point, driven by its flagship ...

Analyst-debate audio for Insmed Incorporated

AskCyborg analysts argue the bull and bear cases for Insmed Incorporated across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
8/ 10Strong

Cyborg Score thesis

Rare disease biopharmaceutical leader with blockbuster-potential launches and significant clinical pipeline driving...

Read the full analyst-debate transcript →
Industry Biopharmaceutical/Specialty Pharma - Rare Diseases
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest Insmed Incorporated Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Insmed Incorporated Overview

Pro stress-test →

Insmed develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company is at a critical inflection point, driven by its flagship product ARIKAYCE and the monumental European approval of BRINSUPRI (brensocatib) in November 2025, a first-in-class therapy for non-cystic fibrosis bronchiectasis.

Strategic Profile

Pro stress-test →

Insmed's business model is centered on the high-value, specialty drug market, where a premium price is justified by treating rare diseases with few or no alternative therapies. The company leverages a focused commercial strategy for rare pulmonary and systemic diseases with strong clinical data and regulatory momentum, positioning it for accelerated revenue growth through newly approved and late-stage pipeline assets.

Competitive Landscape

Pro stress-test →

Key competitors include Ardelyx, Arrowhead Pharmaceuticals, Rallybio, Corcept Therapeutics, and AM-Pharma. Insmed differentiates through focused expertise in rare pulmonary diseases, proprietary specialty formulations (inhaled/inhalation), and first-mover advantages in niche indications with limited therapeutic alternatives.

Industry Context

Insmed Incorporated operates in Biopharmaceutical/Specialty Pharma - Rare Diseases.

Key facts

Founded: 1988 · Headquarters: Bridgewater, New Jersey · Employees: 1,556 · Revenue: $447M · Market cap: $31.9B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Insmed Incorporated.

  • BRINSUPRI (brensocatib) European approval in November 2025 represents monumental achievement as first-in-class therapy for non-cystic fibrosis bronchiectasis
  • ARIKAYCE commands ~$300,000 annualized cost per patient while BRINSUPRI launched with $88,000 yearly list price, supporting premium specialty pricing model
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • November 2025BRINSUPRI (brensocatib) approved in European Union as first-in-class therapy for non-cystic fibrosis bronchiectasis
  • August 2025BRINSUPRI FDA approved in United States; strong early commercial uptake with $28.1M Q3 revenue contribution
  • +1 moreTrack every material event for Insmed Incorporated as it happens. Explore monitoring →
Get alerted when Insmed Incorporated has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Vertex PharmaceuticalsCystic fibrosis and rare diseases therapies→GalapagosRare disease biopharmaceutical company→ArdelyxRare kidney and digestive disease treatments→

Compare Insmed Incorporated with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Insmed Incorporated operates in Biopharmaceutical/Specialty Pharma - Rare Diseases. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical/Specialty Pharma - Rare Diseases research →
NEW · MCP server

Ask your AI assistant about Insmed Incorporated

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Insmed Incorporated and its top competitor on Cyborg Score”
“What did Insmed Incorporated do this quarter?”
“Is Insmed Incorporated a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Insmed Incorporated do?+
Insmed develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company is at a critical inflection point, driven by its flagship ...
What is Insmed Incorporated's Cyborg Score?+
Insmed Incorporated has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Insmed Incorporated's main competitors?+
Named competitors include Vertex Pharmaceuticals, Galapagos, Ardelyx. The full competitive landscape is in the AskCyborg report.
How can I get the full Insmed Incorporated research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Insmed Incorporated research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Insmed Incorporated over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

9Eli Lilly and Company8argenx SE8Ascendis Pharma A/S8Avidity Biosciences, Inc.8BeOne Medicines AG8Celltrion, Inc.8Corcept Therapeutics Incorporated8Roivant Sciences Ltd.8Terns Pharmaceuticals, Inc.8UCB SA6Galapagos NV7Ardelyx, Inc.Top companies in Biopharmaceutical by Cyborg Score